Diseases / Liver Cirrhosis
Liver Cirrhosis
DiseaseLiver cirrhosis is a chronic liver disease characterized by permanent scarring that replaces healthy tissue and progressively impairs liver function. As fibrosis advances, patients can develop portal hypertension, decompensation, and eventual liver failure.
- Trials
- 1251
- Recruiting
- 157
- Completed
- 503
- With results
- 85
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | — | 3 | — | — | — | 5 | — | 8 |
| Phase 1 | 5 | 4 | — | — | 33 | 3 | 1 | — | 9 | — | 55 |
| Phase 1/2 | 2 | 1 | — | 1 | 15 | 2 | 2 | 1 | 14 | — | 38 |
| Phase 2 | 14 | 4 | — | 2 | 51 | 14 | 2 | — | 15 | — | 102 |
| Phase 2/3 | 2 | 2 | — | — | 10 | 2 | — | — | 6 | — | 22 |
| Phase 3 | 6 | 4 | — | 1 | 37 | 9 | 3 | 1 | 14 | — | 75 |
| Phase 4 | 8 | 2 | 1 | 5 | 32 | 6 | 3 | — | 29 | — | 86 |
| Not applicable | 50 | 22 | 6 | 11 | 126 | 18 | 8 | — | 111 | — | 352 |
| Unknown | 70 | 45 | 4 | 30 | 196 | 13 | 7 | 2 | 145 | 1 | 513 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Liver Cirrhosis | 8 | 55 | 38 | 102 | 22 | 75 | 86 | 352 | 513 | 1251 |
| Fibrosis | 1 | 7 | 5 | 16 | 6 | 14 | 10 | 45 | 58 | 162 |
| Non-alcoholic Fatty Liver Disease | — | 5 | 5 | 22 | — | 4 | 4 | 31 | 59 | 130 |
| Hypertension, Portal | — | — | 1 | 8 | 6 | 6 | 11 | 33 | 54 | 119 |
| Carcinoma, Hepatocellular | — | 1 | 1 | 7 | 1 | 4 | 3 | 28 | 52 | 97 |
| Liver Diseases | — | 3 | 4 | 6 | — | 3 | 3 | 24 | 45 | 88 |
| Fatty Liver | — | 1 | 5 | 4 | — | 1 | 3 | 19 | 39 | 72 |
| Hepatic Encephalopathy | — | 1 | 2 | 6 | 1 | 4 | 6 | 21 | 15 | 56 |
| Ascites | — | 3 | — | 7 | 5 | 9 | 3 | 13 | 13 | 53 |
| Hepatitis C | — | 2 | 2 | 8 | 1 | 10 | 4 | 5 | 18 | 50 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Institute of Liver and Biliary Sciences, India | 51 | 1 |
| 2 | Assiut University | 30 | 0 |
| 3 | Post Graduate Institute of Medical Education and Research, Chandigarh | 17 | 4 |
| 4 | Air Force Military Medical University, China | 16 | 1 |
| 5 | Assistance Publique - Hôpitaux de Paris | 16 | 1 |
| 6 | Beijing Friendship Hospital | 15 | 0 |
| 7 | Seoul National University Hospital | 15 | 1 |
| 8 | AstraZeneca | 11 | 0 |
| 9 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 11 | 0 |
| 10 | Northern Jiangsu People's Hospital | 11 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Rifaximin | 21 |
| 2 | Portasystemic Shunt, Transjugular Intrahepatic | 19 |
| 3 | Albumins | 17 |
| 4 | Carvedilol | 14 |
| 5 | Standard of Care | 13 |
| 6 | Propranolol | 12 |
| 7 | entecavir | 11 |
| 8 | Terlipressin | 11 |
| 9 | Lactulose | 10 |
| 10 | Ribavirin | 10 |
Evidence
- Results reported
- 16.9%85 of 503 completed
- Published
- 22.7%114 of 503 completed
- Primary endpoint met
- 25%15 of 60 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 100
- Median duration
- 30months
- Countries
- 75
- Study sites
- 3979
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 40
- Phase 1
- 16
- Phase 1/2
- 42
- Phase 2
- 60
- Phase 2/3
- 74
- Phase 3
- 125
- Phase 4
- 96
- Not applicable
- 90
- Unknown
- 153
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | New Delhi | India | 57 |
| 2 | Barcelona | Spain | 55 |
| 3 | Shanghai | China | 51 |
| 4 | New York | United States | 45 |
| 5 | Seoul | South Korea | 43 |
| 6 | San Antonio | United States | 42 |
| 7 | Beijing | China | 41 |
| 8 | Dallas | United States | 40 |
| 9 | London | United Kingdom | 40 |
| 10 | Boston | United States | 39 |
Terminations
- Terminated
- 67
- Withdrawn
- 26
- Suspended
- 4
- Stopped for recruitment
- 1.9%24 of 1251 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT04199910 Suspended | Suspended | COVID pandemia and organisational changes hinder recruitment | 2027-12-31 |
| NCT04104321 Suspended | Suspended | Interim analysis results from the open-label part of the study. The double blind portion of the study will be resumed once the study will continue. | 2027-06-30 |
| NCT07102979 Terminated | Terminated | Slow recruitment and exhaustion of available study funding. | 2025-12-31 |
| NCT05649202 Withdrawn | Withdrawn | No patient eligible | 2025-07-31 |
| NCT05516498 Terminated | Terminated | The study was ended earlier than planned due to a sponsor decision. | 2025-07-17 |
| NCT05583539 Withdrawn | Withdrawn | Never IRB approved | 2025-06-30 |
| NCT05342350 Terminated | Terminated | PI moving on from current institution | 2025-06-07 |
| NCT06630572 Terminated | Terminated | Because drug is expired | 2024-08-01 |
| NCT03969199 Withdrawn | Withdrawn | Study never started | 2024-07-31 |
| NCT06082843 Terminated | Terminated | Company decision | 2024-05-30 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: